# Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

> **NCT01630967** · PHASE2 · UNKNOWN · sponsor: **British Columbia Cancer Agency** · enrollment: 40 (estimated)

## Conditions studied

- Prostate Neoplasm

## Interventions

- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT01630967
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01630967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01630967, "Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01630967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*